Osteoporosis （OP） is a metabolic disorder characterized by microstructural deterioration of bone and increased bone fragility due to reduced bone mass， which can cause the development of bone-related diseases. This condition imposes significant economic and psychological burdens on patients. While modern medicine has extensively researched the pathogenesis of OP， it remains incompletely understood. Current clinical management primarily relies on anti-resorptive drugs and synthetic metabolic agents. However， long-term use of some medications may yield suboptimal therapeutic outcomes and lead to severe adverse reactions. Given the necessity for prolonged or lifelong treatment for OP， there is a critical need to identify highly effective， safe， and cost-effective pharmaceutical interventions. In light of evolving disease management paradigms and recent advancements in OP research， traditional Chinese medicine has demonstrated emerging advantages in addressing this condition. Through literature review， this study delves into the pathogenesis of OP from five perspectives： hormonal dysregulation， autophagy， ferroptosis， oxidative stress， and intestinal flora alteration. Furthermore， it summarizes the therapeutic efficacy and specific mechanisms of traditional Chinese medicine monomers and compound formulas against OP through regulating hormone levels， interfering with autophagy， inhibiting ferroptosis， counteract oxidative stress，and maintain intestinal flora balance. These multifaceted insights are expected to provide theoretical reference and guide future clinical traditional Chinese medicine approaches for preventing and managing OP.

Objective:This report analyzed the epidemiological characteristics of adenovirus enteritis in hospitalized children based on data from a nationwide multicenter study.Methods:We analyzed patient admission records of children hospitalized for adenoviral enteritis from the FUTang Update medical Records (FUTURE) database. Data were collected from 22 tertiary pediatric hospitals between January 2016 and December 2021. The study focused on identifying epidemiological trends and assessing the disease burden.Results:A total of 1 638 children were hospitalized for adenovirus gastroenteritis, accounting for 0.03% (1 638/5 465 249) of all hospitalizations in this age group and 2.88% (1 638/56 859) of diarrhea-related hospitalizations. The male-to-female ratio was 1.47∶1, with more males affected across all age groups, years, and regions. The majority of hospitalizations (77.41%) occurred among children aged 7 months to 2 years, who also represented the highest proportion (0.070%) of hospitalizations within their age group. Additionally, the number of hospitalizations increased annually from 2016 to 2021, with a noticeable rise in admissions during the summer and autumn months (July-October). Two-thirds of the patients had no significant extraintestinal comorbidities, while approximately one-fifth developed respiratory comorbidities such as pneumonia or acute bronchitis. The median length of hospital stay was 5 days (IQR 3.75-6), and the median hospitalization cost was 4 582.56 RMB (IQR 3 261.52-6 256.87).Conclusions:This study highlights adenovirus gastroenteritis as a significant cause of diarrhea-related hospitalizations in children in China, particularly among those aged 7 months to 2 years. Hospitalization rates were notably higher in males, with a peak in admissions during July to October. Most children experienced no extraintestinal comorbidities.

The national pediatric cancer surveillance data known as the pediatric cancer case report card(report card), had the characteristics of wide sources, diverse collection methods and a large amount of information. Based on the characteristics of the surveillance data, the National Center for Pediatric Cancer Surveillance (surveillance center) established quality control program for surveillance data according to the relevant norms and standards from China and other countries. The program defined the variables, requirements and rules for the quality control of surveillance data. The surveillance center designed different quality control processes according to the way of data reporting including manual filling/file import and port docking, and formulated a series of supporting measures to achieve the completeness, accuracy and standardization of surveillance data. By analyzing the report cards of patients discharged from hospital from 2021 to 2023, the surveillance center found that the number of problem report cards decreased from 40.6% (202 185 cards / 497 538 cards) before feedback to 31.1% (157 725 cards / 506 817 cards) after feedback. The data quality control program not only improved the quality of surveillance data, but also provided references for the establishment of the data quality control program of other registration systems of medical field.

Objective:To explore the clinical characteristics and prognosis of children with chronic myeloid leukemia in the blast phase (CML-BP) .Methods:The clinical characteristics, treatment measures, and survival outcomes of 28 children with CML-BP were analyzed in our hospital from January 2008 to November 2022.Results:The male to female ratio of the 28 children with CML-BP was 1.15∶1. The median age of diagnosis of CML-BP was 10 years, and the median follow-up time was 79 months. During the diagnosis of CML, four children were in the BP, one was in the accelerated phase (AP) and 23 children were in the chronic phase (CP). Among the 23 children with CML-CP, 75% had progressed directly from CP to BP without experiencing the AP. Among the children diagnosed with CML-BP, 71.4% were classified as chronic myeloid leukemia lymphoid blast phase (CML-LBP), 25.0% belonged to the chronic myeloid leukemia myeloid blast phase (CML-MBP), and 3.6% belonged to the chronic myeloid leukemia mixed phenotype acute leukemia (CML-MPAL). Treatment with hemaopoietic stem cell transplantation (HSCT) after tyosine kinase inhibitor (TKI) combined with chemotherapy was administered to 19 children, two children received HSCT after TKI alone, and seven children received TKI combined with chemotherapy but without HSCT. The 5-year overall survival of the 28 children with CML-BP was 59.3%.Conclusion:The direct progression of BP from CP is greater in children with CML-BP compared with adults, and the overall prognosis of children with CML-BP is poor.

Objective:To explore the predictive effect of European treatment and outcome study long term survival (ELTS) score on survival outcomes in chronic myeloid leukemia of chronic phase (CML-CP) children.Methods:A single-center retrospective cohort study was conducted. Clinical data of 216 children with CML-CP in Peking University People′s Hospital from January 2010 to December 2023 were analyzed. Children were divided into low, intermediate and high-risk groups according to ELTS score. The survival outcomes and prognostic factors were analyzed. Kaplan-Meier method and Log-Rank test were used for survival analysis.Cox regression model was applied for analysis of prognostic factors.Results:Among the 216 children with CML-CP, there were 122 males and 94 females, with the diagnosis age of 11.0 (8.0, 14.7) years. The follow-up time was 77 (57, 99) months. According to ELTS score, 145, 52, and 19 children were classified as low, intermediate and high-risk group. For the low-risk and intermediate/high-risk groups, the 6-year failure-free survival (FFS) rates were (83.0±3.1)% and (64.6±5.7)%, the 6-year progression-free survival (PFS) rates were (91.4±2.3)% and (78.7±4.8)%, and the 6-year event-free survival (EFS) rates were (80.8±3.3)% and (64.2±5.7)%, with statistically significant difference ( χ2=9.45, 7.16, 7.40, P=0.002, 0.007, 0.007), respectively.The 6-year overall survival (OS) rates were (98.5±1.0)% and (95.6±2.4)%, without statistically significant difference ( χ2=0.35, P=0.550). Multivariate analysis showed that ELTS score was an independent prognostic factor or tendency for FFS ( HR=1.97, 95% CI 1.11-3.49), PFS ( HR=2.95, 95% CI 1.18-7.39), and no independent prognostic factor for EFS and OS were found. Conclusions:ELTS score at diagnosis can help stratify the risk of children with CML-CP. The children in intermediate/high-risk group are more likely to have treatment failure, disease progression than those in low-risk group, but the predictive ability of ELTS score for OS is limited.

Objectives:To assess the prognostic impact of the neoadjuvant rectal (NAR) score following neoadjuvant short-course radiotherapy and consolidation chemotherapy in locally advanced rectal cancer (LARC), as well as its value in guiding decisions for adjuvant chemotherapy.Methods:Between August 2015 and August 2018, patients were eligible from the STELLAR phase III trial (NCT02533271) who received short-course radiotherapy plus consolidation chemotherapy and for whom the NAR score could be calculated. Based on the NAR score, patients were categorized into low (＜8), intermediate (8-16), and high (＞16) groups. The Kaplan-Meier method, log rank tests, and multivariate Cox proportional hazard regression models were used to evaluate the impact of the NAR score on disease-free survival (DFS).Results:Out of the 232 patients, 24.1%, 48.7%, and 27.2% had low (56 cases), intermediate (113 cases), and high NAR scores (63 cases), respectively. The median follow-up period was 37 months, with 3-year DFS rates of 87.3%, 68.3%, and 53.4% ( P＜0.001) for the low, intermediate, and high NAR score groups. Multivariate analysis demonstrated that the NAR score (intermediate NAR score: HR, 3.10, 95% CI, 1.30-7.37, P=0.011; high NAR scores: HR=5.44, 95% CI, 2.26-13.09, P＜0.001), resection status ( HR, 3.00, 95% CI, 1.64-5.52, P＜0.001), and adjuvant chemotherapy ( HR, 3.25, 95% CI, 2.01-5.27, P＜0.001) were independent prognostic factors for DFS. In patients with R0 resection, the 3-year DFS rates were 97.8% and 78.0% for those with low and intermediate NAR scores who received adjuvant chemotherapy, significantly higher than the 43.2% and 50.6% for those who did not ( P＜0.001, P=0.002). There was no significant difference in the 3-year DFS rate (54.2% vs 53.3%, P=0.214) among high NAR score patients, regardless of adjuvant chemotherapy. Conclusions:The NAR score is a robust prognostic indicator in LARC following neoadjuvant short-course radiotherapy and consolidation chemotherapy, with potential implications for subsequent decisions regarding adjuvant chemotherapy. These findings warrant further validation in studies with larger sample sizes.

Objectives:To assess the prognostic impact of the neoadjuvant rectal (NAR) score following neoadjuvant short-course radiotherapy and consolidation chemotherapy in locally advanced rectal cancer (LARC), as well as its value in guiding decisions for adjuvant chemotherapy.Methods:Between August 2015 and August 2018, patients were eligible from the STELLAR phase III trial (NCT02533271) who received short-course radiotherapy plus consolidation chemotherapy and for whom the NAR score could be calculated. Based on the NAR score, patients were categorized into low (＜8), intermediate (8-16), and high (＞16) groups. The Kaplan-Meier method, log rank tests, and multivariate Cox proportional hazard regression models were used to evaluate the impact of the NAR score on disease-free survival (DFS).Results:Out of the 232 patients, 24.1%, 48.7%, and 27.2% had low (56 cases), intermediate (113 cases), and high NAR scores (63 cases), respectively. The median follow-up period was 37 months, with 3-year DFS rates of 87.3%, 68.3%, and 53.4% ( P＜0.001) for the low, intermediate, and high NAR score groups. Multivariate analysis demonstrated that the NAR score (intermediate NAR score: HR, 3.10, 95% CI, 1.30-7.37, P=0.011; high NAR scores: HR=5.44, 95% CI, 2.26-13.09, P＜0.001), resection status ( HR, 3.00, 95% CI, 1.64-5.52, P＜0.001), and adjuvant chemotherapy ( HR, 3.25, 95% CI, 2.01-5.27, P＜0.001) were independent prognostic factors for DFS. In patients with R0 resection, the 3-year DFS rates were 97.8% and 78.0% for those with low and intermediate NAR scores who received adjuvant chemotherapy, significantly higher than the 43.2% and 50.6% for those who did not ( P＜0.001, P=0.002). There was no significant difference in the 3-year DFS rate (54.2% vs 53.3%, P=0.214) among high NAR score patients, regardless of adjuvant chemotherapy. Conclusions:The NAR score is a robust prognostic indicator in LARC following neoadjuvant short-course radiotherapy and consolidation chemotherapy, with potential implications for subsequent decisions regarding adjuvant chemotherapy. These findings warrant further validation in studies with larger sample sizes.

Objective:This report analyzed the epidemiological characteristics of adenovirus enteritis in hospitalized children based on data from a nationwide multicenter study.Methods:We analyzed patient admission records of children hospitalized for adenoviral enteritis from the FUTang Update medical Records (FUTURE) database. Data were collected from 22 tertiary pediatric hospitals between January 2016 and December 2021. The study focused on identifying epidemiological trends and assessing the disease burden.Results:A total of 1 638 children were hospitalized for adenovirus gastroenteritis, accounting for 0.03% (1 638/5 465 249) of all hospitalizations in this age group and 2.88% (1 638/56 859) of diarrhea-related hospitalizations. The male-to-female ratio was 1.47∶1, with more males affected across all age groups, years, and regions. The majority of hospitalizations (77.41%) occurred among children aged 7 months to 2 years, who also represented the highest proportion (0.070%) of hospitalizations within their age group. Additionally, the number of hospitalizations increased annually from 2016 to 2021, with a noticeable rise in admissions during the summer and autumn months (July-October). Two-thirds of the patients had no significant extraintestinal comorbidities, while approximately one-fifth developed respiratory comorbidities such as pneumonia or acute bronchitis. The median length of hospital stay was 5 days (IQR 3.75-6), and the median hospitalization cost was 4 582.56 RMB (IQR 3 261.52-6 256.87).Conclusions:This study highlights adenovirus gastroenteritis as a significant cause of diarrhea-related hospitalizations in children in China, particularly among those aged 7 months to 2 years. Hospitalization rates were notably higher in males, with a peak in admissions during July to October. Most children experienced no extraintestinal comorbidities.

The national pediatric cancer surveillance data known as the pediatric cancer case report card(report card), had the characteristics of wide sources, diverse collection methods and a large amount of information. Based on the characteristics of the surveillance data, the National Center for Pediatric Cancer Surveillance (surveillance center) established quality control program for surveillance data according to the relevant norms and standards from China and other countries. The program defined the variables, requirements and rules for the quality control of surveillance data. The surveillance center designed different quality control processes according to the way of data reporting including manual filling/file import and port docking, and formulated a series of supporting measures to achieve the completeness, accuracy and standardization of surveillance data. By analyzing the report cards of patients discharged from hospital from 2021 to 2023, the surveillance center found that the number of problem report cards decreased from 40.6% (202 185 cards / 497 538 cards) before feedback to 31.1% (157 725 cards / 506 817 cards) after feedback. The data quality control program not only improved the quality of surveillance data, but also provided references for the establishment of the data quality control program of other registration systems of medical field.

Monogenic inherited skin diseases are a group of clinically rare diseases that include nearly 1000 phenotypically distinct disorders. Through the concerted efforts of researchers in dermatological sciences and related disciplines worldwide, many advances have been made in the etiology and pathogenesis of these diseases in the last 30 years. However, it is important to note that the treatment of the majority of monogenic inherited skin diseases remains a challenge for clinicians. Dupilumab is a fully human monoclonal IgG4 antibody that specifically binds to the α subunit of the IL-4 receptor, thereby inhibiting the IL-4 and IL-13 signaling pathway. It was first approved for the treatment of moderate-to-severe atopic dermatitis (AD) and has been used worldwide. In recent years, the drug has been successfully used to treat some monogenic inherited skin diseases with AD-like clinical manifestations, such as hyper-IgE syndrome and Netherton syndrome, with good efficacy. The drug was later tried for the treatment of other monogenic inherited skin diseases, such as Hailey-Hailey syndrome and epidermolysis bullosa pruriginosa, where it was also proven to be effective. In this paper, we review literature reports related to dupilumab for the treatment of monogenic inherited skin diseases in recent years, focusing on its efficacy, safety and possible therapeutic mechanisms. We aim to provide a possible scientific basis for the future application of this drug in the field of rare monogenic inherited skin diseases.